BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38356719)

  • 1. A pan-cancer characterization of immune-related NFIL3 identifies potential predictive biomarker.
    Fei Q; Zhang X; Wang S; Shu G; Yin G
    J Cancer; 2024; 15(5):1271-1286. PubMed ID: 38356719
    [No Abstract]   [Full Text] [Related]  

  • 2. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
    Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
    Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
    Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
    Front Oncol; 2021; 11():607224. PubMed ID: 34026603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated pan-cancer analysis and experimental verification of the roles of tropomyosin 4 in gastric cancer.
    Guo Q; Zhao L; Yan N; Li Y; Guo C; Dang S; Shen X; Han J; Luo Y
    Front Immunol; 2023; 14():1148056. PubMed ID: 36993958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
    Pan T; Wang S; Wang Z
    J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
    [No Abstract]   [Full Text] [Related]  

  • 9. Pan-cancer Analysis of the Disulfidptosis-related Gene NCKAP1 and Its Prognostic Value for Lung Adenocarcinoma.
    Zhu A; Zong Y; Wei S; Li Y; Fan Y; Liu S; Gao X
    J Cancer; 2023; 14(17):3351-3367. PubMed ID: 37928421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic analysis of
    Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
    Front Genet; 2022; 13():926943. PubMed ID: 35991552
    [No Abstract]   [Full Text] [Related]  

  • 11. Pan-Cancer Analysis and Experimental Validation of CEND1 as a Prognostic and Immune Infiltration-Associated Biomarker for Gliomas.
    Ma J; Lang B; Wang L; Zhou Y; Fu C; Tian C; Xue L
    Mol Biotechnol; 2024 Jun; ():. PubMed ID: 38836983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma.
    Huang X; Zhao L; Jin Y; Wang Z; Li T; Xu H; Wang Q; Wang L
    Front Oncol; 2022; 12():827051. PubMed ID: 35433491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 14. ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma.
    Zhang Y; Pang S; Sun B; Zhang M; Jiao X; Lai L; Qian Y; Yang N; Yang W
    Front Oncol; 2022; 12():884066. PubMed ID: 35912257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
    Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
    Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma.
    Huang S; Hou Y; Hu M; Hu J; Liu X
    BMC Cancer; 2022 Sep; 22(1):995. PubMed ID: 36123627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
    Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
    Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
    Liu Z; Miao J
    Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic pan-cancer analysis identifies
    Chen P; Yang X; Wang P; He H; Chen Y; Yu L; Fang H; Wang F; Huang Z
    Ann Transl Med; 2023 Jan; 11(2):121. PubMed ID: 36819495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.